Spain FDI Screening and M&A in 2026: What Cross‑border Buyers and Sellers Must Know

Foreign investment screening in Spain has become one of the most consequential gating items for cross-border M&A transactions closing in 2026. Under the regime anchored in Article 7 bis of Law 19/2003 and implemented through Royal Decree 571/2023, certain acquisitions by non-Spanish investors require prior authorisation from the Council of Ministers before completion. The transitional regime that extends prior-authorisation obligations to EU and EFTA investors, originally a COVID-era emergency measure, has been renewed once more through Decree‑Law 1/2025, keeping those expanded rules in force until 31 December 2026.

This guide walks deal teams, in-house counsel and private-equity professionals through every practical step: who must file, which sectors trigger scrutiny, how to structure an SPA to manage approval risk, and what realistic timelines to build into transaction timetables.

Legal Framework for Foreign Investment Screening in Spain

Spain’s FDI screening regime draws its authority from a layered set of national and EU instruments. At the EU level, Regulation (EU) 2019/452 established a cooperation mechanism for screening foreign direct investments across Member States. Spain transposed and expanded on this framework through domestic legislation that gives the government broad discretion to block or condition transactions affecting public order, public security or public health.

Key Legislation and Dates

Enforcement Authorities and the Escalation Process

The primary enforcing authority is the Directorate-General for International Trade and Investment within Spain’s Ministry of Industry, Trade and Tourism. Applications for prior authorisation are assessed by a coordinating committee (the Junta de Inversiones Exteriores) before being escalated to the Council of Ministers for a final decision. The Council of Ministers holds exclusive competence to approve, condition or block a transaction. In practice, the Directorate-General serves as the initial point of contact and manages the pre-filing consultation process, which experienced practitioners strongly recommend using before submitting a formal application.

Which Transactions Require Prior Authorisation in Spain in 2026

Prior authorisation under Spain’s foreign investment rules is triggered when three cumulative conditions are met: the investor qualifies as a “foreign” investor, the target operates in a sensitive sector, and the acquisition meets certain control or shareholding thresholds. Understanding each element, and how they interact, is essential for determining whether a planned cross-border M&A transaction in Spain will face screening.

Investor Types and Thresholds

The regime distinguishes between two broad categories of investor, with the transitional extension under Decree‑Law 1/2025 blurring a line that was once more clear-cut.

A critical nuance: the screening applies to the ultimate beneficial owner. An EU-domiciled fund whose limited partners are predominantly non-EU sovereign wealth funds, or whose general partner is ultimately controlled by a non-EU entity, may be treated as a non-EU investor for screening purposes. Deal teams must conduct thorough ownership-chain analysis early in due diligence.

Sensitive Sectors

Royal Decree 571/2023, aligned with the factors set out in EU Regulation 2019/452, defines the sectors that trigger screening. The list includes but is not limited to:

• Critical infrastructure. Energy, transport, water, health, communications, media, data processing or storage, aerospace, defence, electoral and financial infrastructure.
• Critical technologies and dual-use items. Artificial intelligence, robotics, semiconductors, cybersecurity, quantum computing, nuclear technologies, aerospace and defence technologies.
• Supply of critical inputs. Energy, raw materials, food security.
• Access to sensitive information. Personal data or the ability to control such data.
• Media. Freedom and pluralism of the media.
• Defence and national security. Any entity supplying the Spanish armed forces or security services.
• Life sciences and healthcare. Pharmaceutical manufacturing, medical devices, clinical data repositories and biotechnology research with pandemic-preparedness relevance.

Industry observers expect the practical scope of “sensitive” to continue widening, particularly around AI, cloud infrastructure and biotech supply chains. Even where a target’s primary activity is not listed, ancillary operations, such as holding personal-data sets or supplying a defence contractor, can bring it within scope.

Interaction Between FDI Screening Spain and Merger Control

FDI screening and merger control in Spain are separate regimes administered by different authorities, but they frequently apply to the same transaction. Understanding how they interact, and sequencing filings correctly, can prevent costly delays in cross-border M&A.

Parallel Filings: Typical Sequencing Options

The Spanish competition authority, the Comisión Nacional de los Mercados y la Competencia (CNMC), reviews transactions that meet certain turnover and market-share thresholds under the Defence of Competition Act. A transaction may simultaneously trigger:

• FDI prior authorisation, filed with the Directorate-General for International Trade and Investment, decided by the Council of Ministers.
• Merger control clearance, filed with and decided by the CNMC (or the Council of Ministers in exceptional public-interest cases).
• Sectoral regulatory approvals, required in regulated industries such as telecommunications (CNMC as sector regulator), energy (CNMC), banking (Bank of Spain / ECB) or insurance (DGSFP).

In practice, many deal teams file FDI and merger control applications in parallel, since the two review processes run independently. However, the SPA should be structured so that closing is conditioned on obtaining all required clearances. Where the transaction is politically sensitive or involves a high-profile target, early informal engagement with both the Directorate-General and the CNMC is advisable to identify any coordination issues.

Practical FDI Filing in Spain: Step‑by‑Step Checklist and Timeline

This section is the operational core for deal teams planning a filing under Spain’s foreign investment screening regime. Assembling a complete filing at the outset, rather than responding to information requests after submission, is the single most effective way to shorten review times.

Required Documents

• Completed application form. Obtained from the Directorate-General for International Trade and Investment.
• Investor identification and ownership-chain chart. Full corporate structure up to the ultimate beneficial owner, including nationality of each entity in the chain.
• Description of the target and its activities. Detailed narrative covering the target’s business lines, customers, contracts with public entities, and any activity within sensitive sectors.
• Transaction documents. Draft or executed SPA, shareholders’ agreement, and any side letters or ancillary agreements.
• Financing structure. Sources of funds, loan agreements, equity commitment letters.
• National-security risk narrative. A self-assessment explaining why the transaction does not adversely affect public order, public security or public health, or, if risks exist, what mitigation measures are proposed.
• Valuation materials. Independent valuation report or financial model supporting the transaction price.
• Technology and IP disclosures (where relevant). Patents, trade secrets, sensitive data holdings, R&D pipeline documentation, particularly critical for tech FDI Spain transactions and life sciences investment Spain deals.
• Post-acquisition business plan. Employment commitments, planned changes to the board, continuation of existing contracts with the Spanish state or critical-infrastructure operators.
• Powers of attorney and legalisation. Apostilled or consularised powers for representatives acting on behalf of the investor.

Standard Timeline Scenarios

Simple-case scenario: A non-sensitive acquisition by an EU investor where the transitional regime applies but the filing is straightforward might clear in approximately 8–12 weeks from formal filing. Complex-case scenario: A non-EU sovereign-linked fund acquiring a majority stake in a Spanish semiconductor or AI company could face a combined Phase I and Phase II review lasting 5–7 months. Conditional-approval scenario: Where the government requires behavioural or structural remedies (continued supply obligations, board-composition requirements, data-localisation commitments), early indication suggests an additional 1–2 months for negotiation and formalisation.

Common Pitfalls

• Incomplete ownership-chain disclosure. Failure to map through to the ultimate beneficial owner is the most common cause of information requests and clock resets.
• Late identification of sensitive-sector activity. Ancillary contracts with defence entities or holdings of personal data can be overlooked in due diligence.
• Underestimating the transitional regime. EU/EFTA investors assuming they are exempt may discover mid-deal that Decree‑Law 1/2025 still applies.
• Insufficient national-security narrative. A bare-bones submission forces the authority to request supplementary information, adding weeks.
• No pre-filing consultation. Skipping the informal stage removes an opportunity to clarify scope and tailor the filing.
• Filing after signing but before closing without SPA protections. If the authority imposes conditions, parties without appropriate SPA provisions may lack flexibility to comply.
• Ignoring parallel merger-control timelines. FDI clearance without merger-control clearance (or vice versa) does not permit closing.
• Failure to address post-acquisition governance. The Council of Ministers may condition approval on maintaining Spanish board representation or operational independence.
• Outdated valuation or financing evidence. Stale materials trigger requests for updated documentation.
• Language issues. All filings must be in Spanish; poor translations create ambiguity and delay.

Deal Structuring and SPA Drafting to Manage Foreign Investment Screening Spain Risk

Protective SPA drafting is essential wherever a cross-border M&A transaction in Spain may require FDI prior authorisation. The goal is to allocate risk fairly between buyer and seller while preserving deal certainty.

Model Clauses

The following clause outlines are illustrative and should be adapted to the specific transaction with qualified legal counsel.

• Condition precedent, FDI approval. “Completion shall be conditional upon the Buyer having received unconditional prior authorisation from the Spanish Council of Ministers pursuant to Article 7 bis of Law 19/2003 (or confirmation that no such authorisation is required), such condition to be satisfied or waived on or before the Long-Stop Date.”
• Regulatory cooperation covenant. “Each Party shall use its reasonable best efforts to obtain all regulatory approvals required for Completion, including by promptly preparing and filing all applications, providing all information reasonably requested by any governmental authority, and proposing remedies where doing so would not result in a material adverse effect on the target’s business.”
• Interim operating covenants. “Between Signing and Completion, the Seller shall procure that the Target conducts its business in the ordinary course, does not enter into, terminate or materially amend any contract with a governmental entity or critical-infrastructure operator, and does not dispose of, licence or encumber any material intellectual property, in each case without the prior written consent of the Buyer.”

Negotiation Checklist: Sellers vs Buyers

• Sellers should negotiate: a reverse break fee payable by the buyer if FDI clearance is denied or conditions are unacceptable; a defined long-stop date (typically 9–12 months) beyond which the seller can terminate; limitations on the buyer’s obligation to accept remedies that go beyond a specified materiality threshold.
• Buyers should negotiate: broad cooperation obligations from the seller (including access to employees, customers and government contacts for filing purposes); a right to waive the FDI condition if clearance is unlikely but the buyer accepts the enforcement risk; holdback or escrow mechanisms linked to any post-closing commitments imposed by the Council of Ministers.

Sector Spotlights, Tech FDI Spain and Life Sciences Investment Spain

Technology and life sciences are the two sectors attracting the most intense scrutiny under Spain’s FDI screening regime in 2026. Transactions in these areas require enhanced disclosure, earlier engagement with authorities and carefully designed mitigation strategies.

Tech, Required Disclosures and Mitigation Examples

Acquisitions involving artificial intelligence, semiconductor design, cloud and SaaS platforms with cross-border data flows, and cybersecurity companies face particularly close examination. The authorities are focused on potential risks to data sovereignty, continuity of supply to European customers, and technology leakage to non-allied jurisdictions.

Effective mitigations include:

• Establishing data-localisation commitments (hosting EU customer data on EU-based servers).
• Ring-fencing R&D operations through a separate Spanish subsidiary with an independent board.
• Committing to maintain existing contracts with Spanish or EU government customers for a defined period post-completion.
• Implementing information firewalls to prevent access by non-EU parent entities to classified or sensitive IP.

Life Sciences, Required Disclosures and Mitigation Examples

Life sciences investment in Spain, particularly pharmaceutical manufacturing, clinical-trial data repositories, biotech with pandemic-preparedness relevance and medical-device production, triggers screening because of the supply-chain security dimension. The Spanish authorities assess whether a change of ownership could disrupt the supply of essential medicines or allow sensitive clinical data to leave the EU.

Practical mitigations include:

• Guaranteeing continuity of supply to the Spanish national health system (Sistema Nacional de Salud) for a minimum period.
• Maintaining manufacturing capacity in Spain and committing to capital-expenditure levels.
• Limiting the transfer of clinical-trial datasets to jurisdictions outside the EU/EEA.
• Retaining key Spanish management personnel and scientific leadership for a transition period.

Sector-Specific Document and Remedy Overview

Penalties, Retrospective Filings and Enforcement Risks

Completing a transaction that requires prior authorisation in Spain without obtaining it carries significant legal risk. The Council of Ministers may declare the transaction void, require divestiture or impose conditions retroactively. Administrative fines can be levied for failure to comply with filing obligations, and the amounts can be substantial depending on the value of the transaction and the nature of the infringement.

Additionally, Spain’s regime includes a post-closing declaration obligation: once an investment has been completed (with or without prior authorisation, depending on whether the transaction fell within a mandatory-filing category), investors are generally required to file a declaration with the Investment Register within one month. Failure to comply with this declaration obligation is itself an administrative infringement. Industry observers expect enforcement activity to intensify in 2026, particularly in the technology and life-sciences sectors, as the government develops institutional capacity and inter-ministerial coordination under Royal Decree 571/2023.

Quick Decision Matrix: Can You Close Before Filing?

The short answer is: closing before obtaining FDI prior authorisation where one is required is unlawful and exposes both parties to enforcement action. In transactions where it is uncertain whether screening applies, a voluntary pre-filing consultation with the Directorate-General is the safest course. The decision matrix below provides initial orientation, but every transaction should be assessed on its specific facts.

For emergency or time-sensitive transactions, such as distressed-asset acquisitions or public takeover bids, the Directorate-General can, in exceptional circumstances, expedite the review. Early, informal engagement with the authority is critical in these situations. Deal teams should also consider whether structuring the acquisition in phases (an initial minority stake below the threshold, followed by a call option) might allow interim closing while the full approval process runs, though such structures carry their own regulatory risks and should be designed with specialist advice.

Conclusion: Building Foreign Investment Screening Spain Into Your Deal Timetable

Spain’s FDI screening regime is no longer a peripheral compliance consideration, it is a central element of transaction planning for any cross-border M&A deal involving a Spanish target in a sensitive sector. The extension of the transitional regime for EU/EFTA investors to 31 December 2026 under Decree‑Law 1/2025 means that virtually all foreign acquirers must conduct a screening analysis at the outset of due diligence. Getting it right requires early ownership-chain mapping, thorough sector analysis, proactive engagement with the Directorate-General, and SPA drafting that allocates approval risk clearly between buyer and seller. The practical timelines, from 8 weeks in straightforward cases to 7 months in complex reviews, must be built into deal timetables from day one.

With the right preparation and specialist guidance, FDI screening need not derail a deal; but ignoring it, or treating it as an afterthought, can prove extremely costly. Deal teams considering acquisitions in Spain should seek specialist M&A legal advice at the earliest opportunity to assess filing obligations and structure transactions accordingly.

Sources

1. Ministry of Industry / Commerce, Control of Investments
2. UNCTAD, Spain Extends the FDI Screening Regime for EU and EFTA Investors to 2026
3. CMS Expert Guide to Foreign Investment Screening Laws, Spain
4. Uría Menéndez, Spanish FDI Screening Mechanism
5. ICLG, Foreign Direct Investment Regimes Spain 2026
6. White & Case, Foreign Direct Investment Reviews 2026: Spain
7. Banco de España, FDI Economic Context Report